RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook
RxSight (NASDAQ:RXST) reported Q2 sales of 11 Light Delivery Devices (LDDs) and one LDD rental, lowering sales 20% and leaving an installed base of 1,166 units. Cash, cash equivalents and short-term investments were about $209M. It revised 2026 revenue to $140M-$160M, including $110M-$120M RxSight sales and $30M-$40M Alcon collaboration revenue, and raised gross margin outlook to 73%-75%.
How this was made
The 30-second read
Why it matters
The key new trading inputs are the revised 2026 revenue range and higher gross margin guidance, alongside management’s explanation that competitive trialing and softer procedure activity are expected to persist into the rest of 2026.
Market read
Traders can reprice RXST based on updated 2026 revenue and margin ranges and the stated assumption that Q2 headwinds continue through year-end.
What to watch
Collaboration revenue is explicitly subject to SEC filing terms and conditions, so realized Alcon-related revenue could diverge from the $30M-$40M assumption.
Background
RxSight sells Light Delivery Devices (LDDs) and Light Adjustable Lenses (LALs), and has an Alcon collaboration that contributes to 2026 revenue recognized under stated terms.
Ticker impact
RxSight revised full-year 2026 revenue to $140M-$160M, including $30M-$40M from the Alcon collaboration, and raised gross margin to 73%-75%.
Likely choppy trading around the guidance update, with downside risk if headwinds persist and upside if margin expansion holds.
The article provides specific 2026 revenue and gross margin ranges plus stated assumptions (Q2 headwinds continuation) and operational plans (accelerated re-engagement, LAL sales force).
Market effects
Could influence sentiment for premium intraocular lens (IOL) makers by highlighting competitive trialing and procedure-volume sensitivity to consumer sentiment.
No specific regional impact disclosed beyond U.S. sales-force investment.
Alcon collaboration revenue contribution may affect broader ophthalmology partnership expectations, but no geography-specific details provided.
Counterpoint
The raised gross margin outlook may offset revenue softness if the LAL vs LDD mix shift is durable, limiting downside from the 20% sales sink framing.
Key entities
- companyRxSight
NASDAQ-listed intraocular lens technology company revising 2026 revenue and gross margin guidance.
- companyAlcon
Collaboration partner whose agreement contributes $30M-$40M of 2026 revenue recognized, subject to SEC filing terms.
